Literature DB >> 18339342

Guidance for off-label use of drugs.

.   

Abstract

Mesh：

Year:  2008        PMID： 18339342     DOI： 10.1016/S1474-4422(08)70050-4

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  4 in total

Review 1.  Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.

Authors:  Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

2.  Immediate neurological recovery following perispinal etanercept years after brain injury.

Authors:  Edward Tobinick; Helen Rodriguez-Romanacce; Arthur Levine; Tracey A Ignatowski; Robert N Spengler
Journal:  Clin Drug Investig       Date:  2014-05       Impact factor: 2.859

3.  Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.

Authors:  Tracey A Ignatowski; Robert N Spengler; Krishnan M Dhandapani; Hedy Folkersma; Roger F Butterworth; Edward Tobinick
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

4.  Off-label drugs use in neurology outpatient department: A prospective study at a tertiary care teaching hospital.

Authors:  Kunj Arun Gor; Kartik N Shah; Pranav B Joshi; Harsh M Joshi; Devang A Rana; Supriya D Malhotra
Journal:  Perspect Clin Res       Date:  2019-04-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.